0001493152-21-030384.txt : 20211203 0001493152-21-030384.hdr.sgml : 20211203 20211203111629 ACCESSION NUMBER: 0001493152-21-030384 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211202 FILED AS OF DATE: 20211203 DATE AS OF CHANGE: 20211203 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: 22NW Fund, LP CENTRAL INDEX KEY: 0001640809 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40388 FILM NUMBER: 211469100 BUSINESS ADDRESS: STREET 1: 1455 NW LEARY WAY STREET 2: SUITE 400 CITY: SEATTLE STATE: WA ZIP: 98107 BUSINESS PHONE: 206-227-3078 MAIL ADDRESS: STREET 1: 1455 NW LEARY WAY STREET 2: SUITE 400 CITY: SEATTLE STATE: WA ZIP: 98107 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: English Aron R. CENTRAL INDEX KEY: 0001770436 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40388 FILM NUMBER: 211469101 MAIL ADDRESS: STREET 1: 1455 NW LEARY WAY, SUITE 400 CITY: SEATTLE STATE: WA ZIP: 98107 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Anebulo Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001815974 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 851170950 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 1415 RANCH ROAD 629 SOUTH, SUITE 201 CITY: LAKEWAY STATE: TX ZIP: 78734 BUSINESS PHONE: 737 203 5270 MAIL ADDRESS: STREET 1: 1415 RANCH ROAD 629 SOUTH, SUITE 201 CITY: LAKEWAY STATE: TX ZIP: 78734 4 1 ownership.xml X0306 4 2021-12-02 0 0001815974 Anebulo Pharmaceuticals, Inc. ANEB 0001770436 English Aron R. C/O ANEBULO PHARMACEUTICALS, INC. 1415 RANCH ROAD 620 SOUTH, SUITE 201 LAKEWAY TX 78734 1 0 1 1 See Explanation Response 0001640809 22NW Fund, LP 1455 NW LEARY WAY SUITE 400 SEATTLE WA 98107 0 0 0 1 See Explanation Response Common Stock, par value $0.001 per share 2021-12-02 4 P 0 13836 5.30 A 3357401 I 22NW Fund, LP Common Stock, par value $0.001 per share 4654528 I Pharma Investors, LLC This Form 4 is filed jointly by Aron R. English and 22NW Fund, LP (collectively, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities of the Issuer owned directly by other members of the Section 13(d) group and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose. Further, each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. This transaction was executed in multiple trades at prices ranging from $4.50 to $6.00. The price above reflects the weighted average sale price. Securities owned directly by 22NW Fund, LP. Mr. English, as the Manager of 22NW Fund GP, LLC, which is the General Partner of 22NW Fund, LP, may be deemed to beneficially own the securities owned directly by 22NW Fund, LP. Securities owned directly by Pharma Investors, LLC. Mr. English, as the owner of Pharma Investors, LLC, may be deemed to beneficially own the securities owned directly by Pharma Investors, LLC. /s/ Aron R. English 2021-12-03 22NW Fund, LP; By: 22NW Fund GP, LLC; By: /s/ Aron R. English 2021-12-03